Treatments & Interventions
Uramustine
substance
Idarubicin hydrochloride
substance
Idarubicin
substance
Interferon alfa-2b
substance
Plicamycin
substance
Busulphan
substance
Hydroxyurea
substance
Thioguanine
substance
Cyclophosphamide
substance
Bosutinib
substance
Bosutinib monohydrate
substance
Cyclophosphamide monohydrate
substance
Cyclophosphamide anhydrous
substance
Signs & Symptoms
Based on Human Phenotype Ontology (HPO) disease-phenotype annotations.
Myeloproliferative disorder
Always present (100%)HP:0005547
Abnormal basophil morphology
Frequent (30-79%)HP:0001912
Abnormality of granulocytes
Frequent (30-79%)HP:0001911
Hematological abnormality
Frequent (30-79%)HP:0001871
Increased platelet count
Frequent (30-79%)HP:0001894
Increased total leukocyte count
Frequent (30-79%)HP:0001974
Large spleen
Frequent (30-79%)HP:0001744
Loss of appetite
Frequent (30-79%)HP:0004396
Low platelet count
Frequent (30-79%)HP:0001873
Pyrexia
Frequent (30-79%)HP:0001945
Tiredness
Frequent (30-79%)HP:0012378
Chronic myeloid leukemia
HP:0005506
Philadelphia-positive acute lymphoblastic leukemia
HP:0004848
Reduced leukocyte alkaline phosphatase
HP:0004852
Related Conditions
Chronic myeloid leukemia in remission(child)
JCML - Juvenile chronic myeloid leukaemia(child)
Leukaemic infiltration of skin in chronic myeloid leukaemia(child)
Chronic phase chronic myeloid leukemia(child)
Accelerated phase chronic myeloid leukemia(child)
Blastic phase chronic myeloid leukemia(child)
Relapsing chronic myeloid leukemia(child)
Chronic leukemia(parent)
Chronic myeloproliferative disorder (clinical)(parent)
Myeloid leukemia(parent)
Quick Facts
- SNOMED CT
- 92818009
- UMLS CUI
- C0153887
- Fully Specified Name
- Chronic myeloid leukemia (disorder)
- Specialists
- 0
- Diagnostic Biomarkers
- 0
- HPO Phenotypes
- 14
- Known Treatments
- 13
Medical Disclaimer
This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.
Clinical content is derived from the SNOMED CT clinical ontology and curated medical knowledge graphs.